Dipeptides

Global $3 Bn Artificial Sweeteners Market to 2025 with Cargill, Ingredion, Tate & Lyle, Archer Daniels Midland, Ajinomoto, and Celanese Dominating

Retrieved on: 
Wednesday, May 29, 2019
Food and drink, Sugar substitutes, Foods, Ajinomoto, Sweetness, Archer Daniels Midland, Ingredion, Dipeptides

Global Artificial Sweeteners Market is expected to be around USD 3 Billion by the end of the year 2025.

Key Points: 
  • Global Artificial Sweeteners Market is expected to be around USD 3 Billion by the end of the year 2025.
  • It is also called High-Intensity sweeteners or Intense sweeteners because the sweetness of artificial sweetener is many times higher than regular sugar.
  • In China, the consumer becomes more health conscious and shift towards artificial sweeteners to prevent themselves from lifestyle ailment.
  • Some of the key players in the global artificial sweeteners market include Cargill, Ingredion, Tate & Lyle, Archer Daniels Midland Company, Ajinomoto Co. Inc., and Celanese Corporation.

Oncopeptides to Present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

Retrieved on: 
Tuesday, May 28, 2019
Dipeptides, Melflufen, Prodrugs, Chemistry

This information was submitted for publication at 10.00 CET May 28, 2019.

Key Points: 
  • This information was submitted for publication at 10.00 CET May 28, 2019.
  • Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer.
  • The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC).
  • Oncopeptides' headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Oncopeptides to Present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

Retrieved on: 
Tuesday, May 28, 2019
Dipeptides, Melflufen, Prodrugs, Chemistry

This information was submitted for publication at 10.00 CET May 28, 2019.

Key Points: 
  • This information was submitted for publication at 10.00 CET May 28, 2019.
  • Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer.
  • The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC).
  • Oncopeptides' headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Natural Alternatives International Announces Participation as Exhibitor and Sponsor in the 2019 Integrative Healthcare Symposium

Retrieved on: 
Wednesday, January 23, 2019
Branches of biology, Medicine, Dipeptides, Clinical medicine, Carnosine, Β-Alanine, Alanine transaminase

This three-day event will be held on February 21-23, 2019, at the New York Hilton in Midtown, New York.

Key Points: 
  • This three-day event will be held on February 21-23, 2019, at the New York Hilton in Midtown, New York.
  • A powerful natural antioxidant, carnosine has been rigorously researched and clinically proven to provide support for muscle, cognitive and systemic function.
  • For more information and to register for the Integrative Healthcare Symposium, please visit www.ihsymposium.com .
  • CarnoSynBrands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyninstant release beta-alanine and SR CarnoSynsustained release beta-alanine.